Rapport Therapeutics leverages discoveries by its scientific founders to identify and target receptor-associated proteins (RAPs) that display regional or neural circuit-specific expression, aiming for more precise modulation of neural receptors. The company’s platform, built and refined over the past decade, is designed to reduce unwanted drug-target interactions that cause side effects and suboptimal dosing with current treatments. Rapport’s first program, intended to treat seizure disorders resistant to current therapies, is in Phase 1 clinical studies; the company also has ongoing clinical programs in seizure and psychiatric disorders and plans to expand its pipeline. In June the company appointed a scientific advisory board that includes two Nobel laureates and world-renowned experts in ion channel signaling and seizure disorders. Rapport recently completed a $150 million Series B financing to support advancement of its platform and clinical programs. The company operates out of Boston and San Diego. Rapport Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision medicines for neurological disorders. The company’s platform leverages receptor-associated proteins (RAPs) to identify small-molecule drugs that selectively target receptors in specific neuroanatomical regions and neural circuits. That precision approach aims to improve efficacy and tolerability compared with therapies that act on targets expressed ubiquitously across the nervous system. Rapport’s lead program is in Phase 1 studies for the treatment of drug-resistant seizure disorders, and the company is advancing a portfolio of clinical and preclinical compounds. Rapport also incorporates decades of neuroscience research from the Janssen Neuroscience team to fuel its discovery engine. The company launched with significant institutional backing and leadership committed to developing transformational neuroscience medicines.

Total raised

$250M

Funding rounds

2

Latest round

Series B

Latest activity

Aug 2023